RXRX
Recursion Pharmaceuticals, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Strong buy
+60/100
Last price
4.65
▼ 0.13 (2.72%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
4.78
Prev close
4.78
Day high
5.19
Day low
4.40
Volume
71.05M
Market cap
$2.48B
P/E (TTM)
—
52W range
2.77 – 7.18
Day trading desk
Gap from prior close
+0.01%
Prior close 4.78
VWAP
4.64
+0.21% from price
Relative volume
7.19×
Unusually busy
Session range
18.09%
4.39 – 5.19
Position in range
32%
Mid range
ATR (14D)
0.36
7.77% of price
Prior day high
4.93
PDH
Prior day low
4.06
PDL
Bid / ask spread
—
Quote not published
Session volume
140.08M
Avg 19.48M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+14.89%
+12.9%
1M
+27.55%
+26.4%
3M
+24.46%
+19.9%
6M
+45.14%
+27.0%
YTD
+13.20%
-1.0%
1Y
-15.66%
-32.1%
3Y
-39.48%
-121.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on RXRX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+423.48K
Net buying
Buy transactions
15
867.82K shares
Sell transactions
15
444.35K shares
Net transactions
+30
Buys less sells
Sell : buy shares
0.5 : 1
Mixed
Insider-held shares
10.94M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 8, 26 | KHAN NAJAT Chief Executive Officer |
SELL | 22.41K | $78.82K | Direct |
| Sep 1, 26 | BORGESON BLAKE CHARLES Director |
SELL | 30.00K | $100.20K | Direct |
| Aug 4, 26 | BORGESON BLAKE CHARLES Director |
SELL | 30.00K | $97.50K | Direct |
| Jul 7, 26 | BORGESON BLAKE CHARLES Director |
SELL | 40.00K | $158.50K | Direct |
| Jul 1, 26 | LI DEAN Y Director |
STOCK | 3.75K | $0 | Direct |
| Jul 1, 26 | DAR ZAVAIN Director |
STOCK | 5.11K | $0 | Direct |
| Jun 18, 26 | BUMPUS NAMANDJE N. Director |
SELL | 3.96K | $12.60K | Direct |
| Jun 17, 26 | HERSHBERG ROBERT M Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | SUN ELAINE D Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | LI DEAN Y Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | BORGESON BLAKE CHARLES Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | DAR ZAVAIN Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | MICHOR FRANZISKA PH.D. Director |
STOCK | 88.42K | $0 | Direct |
| Jun 17, 26 | BUMPUS NAMANDJE N. Director |
STOCK | 88.42K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BORGESON BLAKE CHARLES |
Director | 6.16M | Sale |
DAR ZAVAIN |
Director | 240.76K | Stock Award(Grant) |
GIBSON CHRISTOPHER C. |
Director | 883.74K | Sale |
HALLETT DAVID |
Officer | 1.11M | Stock Award(Grant) |
KHAN NAJAT |
Chief Executive Officer | 2.07M | Sale |
LI DEAN Y |
Director | 3.32M | Stock Award(Grant) |
MARRIOTT TINA LARSON |
President | 521.14K | Sale |
MICHOR FRANZISKA PH.D. |
Director | 215.48K | Stock Award(Grant) |
SECORA MICHAEL |
Chief Financial Officer | 1.50M | Sale |
TAYLOR BEN R |
Chief Financial Officer | 1.18M | Sale |
Fundamentals
Market cap$2.48B
Enterprise value$2.00B
Revenue (TTM)$54.86M
Gross profit$-392.60M
EBITDA$-471.60M
Net income$-518.88M
EPS (TTM)$-0.97
Free cash flow$-219.49M
Total cash$545.68M
Total debt$66.64M
Book value / share$1.71
Shares outstanding535.34M
Float518.46M
Short % of float34.95%
Dividend yield0.00%
Beta (5Y)1.03
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.13
PEG ratio—
Price / sales—
Price / book2.71
EV / revenue36.45
EV / EBITDA-4.24
Gross margin0.00%
Operating margin-1759.69%
Profit margin0.00%
Return on equity-56.58%
Return on assets-27.33%
Debt / equity7.28
Current ratio5.03
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $74.26M | $58.49M | $43.88M | $39.68M | +27.0% |
| Operating revenue | $74.26M | $58.49M | $43.88M | $39.68M | +27.0% |
| Cost of revenue | $70.95M | $45.24M | $42.59M | $48.27M | +56.8% |
| Gross profit | $3.30M | $13.25M | $1.29M | -$8.59M | -75.1% |
| Research & development | $475.27M | $314.42M | $241.23M | $155.70M | +51.2% |
| Selling, general & admin | $176.59M | $178.18M | $110.82M | $81.60M | -0.9% |
| Total operating expense | $651.43M | $492.25M | $351.35M | $237.13M | +32.3% |
| Operating income | -$648.13M | -$479.00M | -$350.06M | -$245.73M | -35.3% |
| Net interest income | $20.98M | $14.19M | $19.02M | $6.20M | +47.9% |
| Pre-tax income | -$644.89M | -$464.79M | -$332.13M | -$239.48M | -38.8% |
| Tax provision | -$136.00K | -$1.13M | -$4.06M | $0 | +87.9% |
| Net income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -39.1% |
| Net income to common | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -39.1% |
| Basic EPS | -1.44 | -1.69 | -1.58 | -1.36 | +14.8% |
| Diluted EPS | -1.44 | -1.69 | -1.58 | -1.36 | +14.8% |
| EBIT | -$643.09M | -$463.22M | -$332.03M | -$239.42M | -38.8% |
| EBITDA | -$559.38M | -$426.72M | -$307.63M | -$227.66M | -31.1% |
| Basic shares | 447.45M | 274.21M | 207.85M | 175.54M | +63.2% |
| Diluted shares | 447.45M | 274.21M | 207.85M | 175.54M | +63.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $743.29M | $594.35M | $391.56M | $549.91M | — | +25.1% |
| Cash & short-term investments | $743.29M | $594.35M | $391.56M | $549.91M | — | +25.1% |
| Accounts receivable | — | — | — | $0 | $34.00K | — |
| Total current assets | $812.85M | $714.27M | $438.14M | $569.81M | — | +13.8% |
| Property, plant & equipment | $169.48M | $233.21M | $120.17M | $121.45M | — | -27.3% |
| Goodwill & intangibles | $472.06M | $484.73M | $88.50M | $2.11M | — | -2.6% |
| Total assets | $1.47B | $1.45B | $653.70M | $701.29M | — | +1.8% |
| Total current liabilities | $147.71M | $187.47M | $93.17M | $100.27M | — | -21.2% |
| Current debt | $9.09M | $8.43M | $41.00K | $97.00K | — | +7.9% |
| Long-term debt | $9.56M | $19.02M | $1.10M | $536.00K | — | -49.7% |
| Total debt | $77.97M | $108.49M | $50.67M | $51.01M | — | -28.1% |
| Total liabilities | $343.26M | $413.82M | $190.26M | $215.48M | — | -17.0% |
| Retained earnings | -$2.08B | -$1.43B | -$967.62M | -$639.56M | — | -45.0% |
| Shareholder equity | $1.13B | $1.03B | $463.44M | $485.81M | — | +9.3% |
| Working capital | $665.14M | $526.80M | $344.97M | $469.55M | — | +26.3% |
| Net tangible assets | $658.80M | $550.05M | $374.94M | $483.70M | — | +19.8% |
| Shares issued | 528.18M | 396.80M | 234.27M | 191.02M | — | +33.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$644.76M | -$463.66M | -$328.07M | -$239.48M | -39.1% |
| Depreciation & amortisation | $83.70M | $36.49M | $24.40M | $11.76M | +129.4% |
| Stock-based compensation | $111.22M | $81.69M | $53.50M | $27.91M | +36.2% |
| Change in working capital | $13.69M | -$46.76M | -$44.26M | $104.92M | +129.3% |
| Operating cash flow | -$371.81M | -$359.17M | -$287.78M | -$83.52M | -3.5% |
| Capital expenditure | -$8.63M | -$17.05M | -$12.55M | -$37.36M | +49.4% |
| Investing cash flow | -$16.87M | $260.06M | -$10.23M | $193.25M | -106.5% |
| Financing cash flow | $521.53M | $304.12M | $140.13M | $154.34M | +71.5% |
| Free cash flow | -$380.44M | -$376.22M | -$300.33M | -$120.88M | -1.1% |
| End cash position | $753.92M | $603.02M | $401.43M | $559.11M | +25.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $7.30M | $6.30M | $35.35M | $4.98M | $19.10M | +15.9% |
| Operating revenue | $7.30M | $6.30M | $35.35M | $4.98M | $19.10M | +15.9% |
| Cost of revenue | $11.49M | $12.49M | $14.28M | $14.69M | $20.16M | -8.0% |
| Gross profit | -$4.19M | -$6.19M | $21.08M | -$9.70M | -$1.06M | +32.3% |
| Research & development | $89.61M | $87.90M | $95.94M | $121.06M | $128.64M | +2.0% |
| Selling, general & admin | $41.53M | $34.59M | $33.66M | $41.63M | $46.65M | +20.1% |
| Total operating expense | $130.78M | $122.32M | $129.41M | $162.50M | $175.17M | +6.9% |
| Operating income | -$134.97M | -$128.50M | -$108.33M | -$172.20M | -$176.23M | -5.0% |
| Net interest income | $5.00M | $5.61M | $6.26M | $4.71M | $4.96M | -11.0% |
| Pre-tax income | -$131.01M | -$122.11M | -$108.10M | -$162.25M | -$171.90M | -7.3% |
| Tax provision | -$1.00K | -$4.60M | $20.00K | $3.00K | $0 | +100.0% |
| Net income | -$131.00M | -$117.50M | -$108.12M | -$162.25M | -$171.90M | -11.5% |
| Net income to common | -$131.00M | -$117.50M | -$108.12M | -$162.25M | -$171.90M | -11.5% |
| Basic EPS | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -13.6% |
| Diluted EPS | -0.25 | -0.22 | -0.21 | -0.36 | -0.41 | -13.6% |
| EBIT | -$130.70M | -$121.76M | -$108.11M | -$161.42M | -$171.42M | -7.3% |
| EBITDA | -$112.53M | -$102.08M | -$88.63M | -$140.37M | -$147.57M | -10.2% |
| Basic shares | 532.46M | 529.30M | 526.72M | 446.99M | 417.36M | +0.6% |
| Diluted shares | 532.46M | 529.30M | 526.72M | 446.99M | 417.36M | +0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $545.68M | $654.47M | $743.29M | $659.84M | $525.11M | -16.6% |
| Cash & short-term investments | $545.68M | $654.47M | $743.29M | $659.84M | $525.11M | -16.6% |
| Total current assets | $603.46M | $709.56M | $812.85M | $714.11M | $587.16M | -15.0% |
| Property, plant & equipment | $147.07M | $157.32M | $169.48M | $181.24M | $193.60M | -6.5% |
| Goodwill & intangibles | $443.24M | $454.24M | $472.06M | $484.39M | $505.59M | -2.4% |
| Total assets | $1.21B | $1.34B | $1.47B | $1.40B | $1.30B | -9.5% |
| Total current liabilities | $119.89M | $129.70M | $147.71M | $155.10M | $164.03M | -7.6% |
| Current debt | $9.44M | $9.27M | $9.09M | $8.92M | $8.75M | +1.9% |
| Long-term debt | $4.75M | $7.18M | $9.56M | $11.90M | $14.20M | -33.8% |
| Total debt | $66.64M | $72.38M | $77.97M | $82.37M | $88.08M | -7.9% |
| Total liabilities | $297.67M | $314.75M | $343.26M | $352.58M | $383.21M | -5.4% |
| Retained earnings | -$2.32B | -$2.19B | -$2.08B | -$1.97B | -$1.81B | -6.0% |
| Shareholder equity | $915.00M | $1.02B | $1.13B | $1.05B | $919.15M | -10.7% |
| Working capital | $483.58M | $579.86M | $665.14M | $559.00M | $423.13M | -16.6% |
| Net tangible assets | $471.76M | $570.53M | $658.80M | $562.56M | $413.56M | -17.3% |
| Shares issued | 534.12M | 530.63M | 528.18M | 491.80M | 432.83M | +0.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$131.00M | -$117.50M | -$108.12M | -$162.25M | -$171.90M | -11.5% |
| Depreciation & amortisation | $18.17M | $19.67M | $19.48M | $21.04M | $23.85M | -7.7% |
| Stock-based compensation | $19.50M | $22.21M | $23.76M | $25.24M | $26.16M | -12.2% |
| Change in working capital | -$18.56M | -$7.80M | $10.68M | -$26.30M | $35.15M | -137.8% |
| Operating cash flow | -$105.95M | -$81.10M | -$46.07M | -$117.36M | -$76.42M | -30.6% |
| Capital expenditure | -$1.96M | -$338.00K | -$1.24M | -$243.00K | -$5.31M | -479.6% |
| Investing cash flow | -$1.96M | -$338.00K | -$1.24M | -$2.55M | -$5.81M | -479.6% |
| Financing cash flow | -$1.27M | -$3.47M | $132.01M | $251.34M | $97.66M | +63.5% |
| Free cash flow | -$107.91M | -$81.44M | -$47.32M | -$117.60M | -$81.73M | -32.5% |
| End cash position | $556.82M | $665.18M | $753.92M | $667.14M | $533.85M | -16.3% |
Options analytics
Put / call volume
0.14
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
0.50
-89.2% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+25.0%
Puts bid over calls
Call volume
9.64K
Contracts, this expiry
Put volume
1.36K
Contracts, this expiry
Heaviest call OI
0.50
0 contracts
Heaviest put OI
0.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.23 | -0.25 | -6.8% |
| Mar 2026 | -0.26 | -0.22 | +14.4% |
| Dec 2025 | -0.32 | -0.21 | +33.3% |
| Sep 2025 | -0.38 | -0.36 | +5.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.23 | 6 | $13.04M | +152.0% |
| Next quarter | -0.23 | 6 | $13.47M | -62.1% |
| Current year | -0.93 | 7 | $38.81M | -48.0% |
| Next year | -0.90 | 7 | $52.38M | +35.0% |
Analyst targets & ownership
Mean target$7.22
High target$10.00
Low target$4.00
Implied upside55.20%
Analyst count6
ConsensusNONE
Strong buy / Buy2 / 1
Hold4
Sell / Strong sell0 / 0
Held by insiders2.04%
Held by institutions71.58%
Institutions holding449
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
4.08
+14.00% from price
SMA 20
3.78
+22.49% from price
SMA 50
3.49
+32.78% from price
SMA 100
3.39
+37.19% from price
SMA 200
3.58
+29.50% from price
EMA 12
4.11
+13.18% from price
EMA 26
3.83
+21.44% from price
EMA 50
3.63
+28.16% from price
RSI (14)
67.5
Neutral
MACD (12,26,9)
0.28
Hist 0.09
ATR (14)
0.36
7.81% of price
Realised vol 30D
85.5%
Annualised
Bollinger upper
4.69
20, 2σ
Bollinger lower
2.87
20, 2σ
50 / 200 cross
Death
3.49 vs 3.58
Trend bias
Above 200
+29.50%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.91
More volatile than market
Correlation to SPY
0.50
Loosely linked
Realised vol 30D
85.5%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-58.2%
Peak to trough
Max drawdown 5Y
-86.3%
Peak to trough
ATR 14
0.36
7.81% of price
Beta (reported)
1.03
5Y monthly, from filing
Short interest
Shares short
178.72M
Prior 177.92M
Change vs prior
+0.5%
Shorts adding
% of float
34.95%
Heavily shorted
% of shares out
33.33%
Against total outstanding
Days to cover
11.3
Crowded exit
Float
518.46M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 14, 26 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 7, 26 | Needham | MAINTAINED | Buy | Buy |
| Apr 30, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Feb 26, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Feb 26, 26 | Needham | MAINTAINED | Buy | Buy |
| Dec 17, 25 | JP Morgan | UPGRADE | Neutral | Overweight |
| Sep 11, 25 | Needham | MAINTAINED | Buy | Buy |
| Jul 8, 25 | Needham | MAINTAINED | Buy | Buy |
| Jun 16, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| May 6, 25 | Needham | MAINTAINED | Buy | Buy |
| Apr 10, 25 | Morgan Stanley | MAINTAINED | Equal-Weight | Equal-Weight |
| Apr 8, 25 | Needham | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-21
Periodic Financial Reports
10-Q · 2026-08-05
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-05-06
Corporate Changes & Voting Matters
8-K · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-03-25
Offering Registrations
S-8 · 2026-02-25
Corporate Changes & Voting Matters
8-K · 2026-01-12
Headlines
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors
Zacks · 9h ago
BC-Most Active Stocks
Associated Press · 15h ago
Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST Shares
Stocktwits · 17h ago
Ondas, SoundHound AI Lead Wall Street's Most Shorted Stocks
GuruFocus.com · 1d ago
BC-Most Active Stocks
Associated Press · 2d ago
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note
Zacks · 8d ago
Analysts move HubSpot 29 places higher in power ranking
TheStreet · 12d ago
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
Zacks · 13d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.